In a report released today, Nick Setyan from Wedbush maintained a Buy rating on McDonald’s (MCD – Research Report), with a price target of $270.00. The company’s shares closed last Tuesday at $257.09.
According to TipRanks.com, Setyan is a 4-star analyst with an average return of 3.9% and a 43.4% success rate. Setyan covers the Services sector, focusing on stocks such as Papa John’s International, The ONE Group Hospitality, and Brinker International.
McDonald’s has an analyst consensus of Strong Buy, with a price target consensus of $281.08, a 12.6% upside from current levels. In a report issued on July 18, Morgan Stanley also maintained a Buy rating on the stock with a $285.00 price target.
Based on McDonald’s’ latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $5.67 billion and net profit of $1.1 billion. In comparison, last year the company earned revenue of $5.12 billion and had a net profit of $1.54 billion.
Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of MCD in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Founded in 1955, McDonald’s Corp. is world’s leading fast food chain that operates and franchises over 30,000 restaurants in more than 100 countries. More than 90% of McDonald’s restaurants are owned and operated by independent local business owners. Its popular products include Big Mac, Quarter Pounder with Cheese, Filet-O-Fish, Chicken McNuggets, McDonald’s Fries, McFlurry desserts, and McCafé beverages, among others. The company is headquartered in Oak Brook, Illinois.
Read More on MCD:
- Investors Are Lovin’ McDonald’s Q2 Earnings Beat, Solid Comparable Sales
- New Buy Rating for Microsoft (MSFT), the Technology Giant
- H.C. Wainwright Thinks Rani Therapeutics Holdings’ Stock is Going to Recover
- H.C. Wainwright Thinks Clearside Biomedical’s Stock is Going to Recover
- Assembly Biosciences (ASMB) Gets a Hold Rating from H.C. Wainwright